Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Elena Guerini, Patrizia Mancuso, Cristina Noberasco, Ester Del Signore, Valentina Labanca, Chiara Catania, Francesco Bertolini, Sara Gandini, Alessia Pochesci, Massimo Barberis, Antonio Passaro, Filippo de Marinis, Gianluca Spitaleri
Publikováno v:
Cancer Research. 77:2635-2635
The anti-PD-1 monoclonal antibody nivolumab is clinically active in a variety of tumor types including squamous (sq) and non-squamous (non-sq) NSCLC in second-line, where randomized phase III trials have shown a survival benefit. However, no predicti
Autor:
Jordi Codony, Filippo de Marinis, Jose Miguel Sanchez, Miguel Angel Molina-Vila, Mariano Provencio, Xueting Cai, Jose Luis Ramirez, Patrick C. Ma, Enric Carcereny, Trever G. Bivona, Sara Pilotto, Silvia Marin, Carles Codony, Alain Vergnenegre, Caicun Zhou, Rosario García-Campelo, X. Li, Cristina Teixidó, Niki Karachaliou, Roger Estrada, Peng Cao, Andrés F. Cardona, Isabella Sperduti, Imane Chaib, Noemi Reguart, Raimon Puig de la Bellacasa, Guillermo Lopez-Vivanco, Rafael Rosell, Sonia Rodríguez, Ana Drozdowskyj
Publikováno v:
Cancer Research. 76:265-265
Intrinsic or acquired resistance limits the clinical effectiveness of EGFR tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations. One of the signaling mediators downstream of activated EGFR is signa